高级检索
当前位置: 首页 > 详情页

Chinese medicine Fufang Zhenzhu Tiaozhi capsule ameliorates coronary atherosclerosis in diabetes mellitus-related coronary heart disease minipigs

文献详情

资源类型:
Pubmed体系:
机构: [1]Institute of Chinese Medicine, Guangdong Pharmaceutical University, Guangzhou 510006, China [2]Key Unit of Modulating Liver to Treat Hyperlipemia SATCM (State Administration of Traditional Chinese Medicine), SATCM Level 3 Lab of Lipid Metabolism, Guangzhou 510006, China [3]Guangdong TCM Key Laboratory of Metabolic Diseases, Guangzhou 510006, China [4]Key Laboratory of Glucolipid Metabolic Disorder, Ministry of Education, Guangzhou 510006, China [5]Guangdong Metabolic Diseases Research Center of Integrated Chinese and Western Medicine, Guangdong Pharmaceutical University, Guangzhou 510006, China [6]Department of Cardiology, The First Affiliated Hospital of Guangdong Pharmaceutical University, Guangzhou 510080, Guangdong, China
出处:
ISSN:

关键词: Coronary atherosclerosis Chinese medicine Inflammation Apoptosis Endothelial-mesenchymal transitio

摘要:
Diabetes mellitus-related coronary heart disease (DM-CHD) is the most common cause of death in diabetic patients. Various studies have shown that Chinese medicine Fufang-Zhenzhu-Tiaozhi capsule (FTZ) has therapeutic effects on cardiovascular diseases. More research is required to determine the mechanism of FTZ protection against coronary atherosclerosis.To investigate the unique mechanism of FTZ in treatment of DM-CHD minipigs with coronary atherosclerosis.High-fat/high-sucrose/high-cholesterol diet combined with streptozotocin and coronary balloon injury were used to induce DM-CHD minipig model, which was then randomly divided into: DM-CHD model, DM-CHD treated with FTZ or positive drug (Metformin + Atorvastatin, M+A). After twenty-two weeks, ultrasonography, electrocardiography, and image detection were employed to detect cardiac functions and assess coronary artery stenosis and plaque. Human umbilical vein endothelial cells (HUVECs) were treated high glucose or/and FTZ. Pigs tissues and treated-cells were collected for further testing.In DM-CHD minipigs, FTZ treatment significantly reduced disordered glycolipid metabolism similar as M+A administration. FTZ and M+A also alleviated coronary stenosis and myocardial injury. In addition, IκB and NF-κB phosphorylation levels, as well as the protein levels of IL-1β, Bax, cleave-Caspase 3, Bcl-2, and α-SMA were dramatically increased in the DM-CHD coronary artery, whereas CD31 and VE-cadherin expressions were decreased. Similar to M+A, FTZ reversed these protein levels in the DM-CHD coronary artery. Furthermore, FTZ ameliorated the damage and high migration activity of HUVECs induced by high glucose.FTZ improves coronary atherosclerosis through modulating inflammation, alleviating apoptosis, and inhibiting EndMT of coronary artery to protects against DM-CHD.Copyright © 2022 The Authors. Published by Elsevier Masson SAS.. All rights reserved.

基金:
语种:
PubmedID:
中科院(CAS)分区:
出版当年[2021]版:
大类 | 2 区 医学
小类 | 1 区 药学 2 区 医学:研究与实验
最新[2025]版:
大类 | 2 区 医学
小类 | 2 区 医学:研究与实验 2 区 药学
第一作者:
第一作者机构: [1]Institute of Chinese Medicine, Guangdong Pharmaceutical University, Guangzhou 510006, China [2]Key Unit of Modulating Liver to Treat Hyperlipemia SATCM (State Administration of Traditional Chinese Medicine), SATCM Level 3 Lab of Lipid Metabolism, Guangzhou 510006, China [3]Guangdong TCM Key Laboratory of Metabolic Diseases, Guangzhou 510006, China [4]Key Laboratory of Glucolipid Metabolic Disorder, Ministry of Education, Guangzhou 510006, China [5]Guangdong Metabolic Diseases Research Center of Integrated Chinese and Western Medicine, Guangdong Pharmaceutical University, Guangzhou 510006, China
共同第一作者:
通讯作者:
通讯机构: [1]Institute of Chinese Medicine, Guangdong Pharmaceutical University, Guangzhou 510006, China [2]Key Unit of Modulating Liver to Treat Hyperlipemia SATCM (State Administration of Traditional Chinese Medicine), SATCM Level 3 Lab of Lipid Metabolism, Guangzhou 510006, China [3]Guangdong TCM Key Laboratory of Metabolic Diseases, Guangzhou 510006, China [4]Key Laboratory of Glucolipid Metabolic Disorder, Ministry of Education, Guangzhou 510006, China [5]Guangdong Metabolic Diseases Research Center of Integrated Chinese and Western Medicine, Guangdong Pharmaceutical University, Guangzhou 510006, China [*1]Key Laboratory of Glucolipid Metabolic Disorder, Ministry of Education, Guangzhou 510006, China.
推荐引用方式(GB/T 7714):
APA:
MLA:

资源点击量:2018 今日访问量:0 总访问量:645 更新日期:2024-07-01 建议使用谷歌、火狐浏览器 常见问题

版权所有©2020 广东省中医院 技术支持:重庆聚合科技有限公司 地址:广州市越秀区大德路111号